Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie jednego z trzech typów chłoniaka: chłoniak Hodgkina, agresywny chłoniak non-Hodgkina lub chłoniak z komórek T
- •Komórki nowotworu muszą wykazywać cechę CD30
- •Wiek od 12 do 75 lat
- •Dobra ogólna kondycja fizyczna (wynik Karnofsky'ego powyżej 60%)
- •Prawidłowe funkcje nerek (GFR > 70)
- •Wyzdrowiał po poprzedniej chemioterapii
- •Gotowość do stosowania antykoncepcji przez czas badania i 6 miesięcy po
- •Świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Otrzymał inną eksperymentalną terapię komórkową w ciągu ostatnich 6 tygodni
- •Otrzymał terapię opartą na przeciwciałach anty-CD30 w ciągu ostatnich 4 tygodni
- •Ciąża lub karmienie piersią
- •Guz mogący blokować drogi oddechowe w przypadku powiększenia
- •Stosowanie wysokich dawek kortykosteroidów (więcej niż 10 mg prednizonu dziennie)
- •Aktywna, niekontrolowana infekcja bakteryjna, wirusowa lub grzybiczna
- •Problemy z sercem powodujące objawy
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Houston Methodist Hospital
Houston, United States
Texas Children's Hospital
Houston, United States
Trial contact
Carlos Ramos, MD
Vicky Torrano
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.